Cingulate Inc.
CINGClinical-stage pharmaceutical company developing ADHD treatments
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 18, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CING Earnings Report
EPS Est: $-0.63 | FQ end 2026-06
How CING's past catalysts played out
CTx-1301 - Dexmethylphenidate 25mg
ADHD
CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
ADHD
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
ADHD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTx-1301 - Dexmethylphenidate 25mg | Phase 3 | ADHD | - | - |
CTx-1301-Dexmethylphenidate 12.5 mg (titration only) | Phase 3 | ADHD | - | - |
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release | Phase 2 | ADHD | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cingulate Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cingulate Inc.'s (CING) pipeline across Phase 3, Phase 2. Its lead program is CTx-1301 - Dexmethylphenidate 25mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cingulate Inc.'s next FDA catalyst?→
Cingulate Inc.'s (CING) next tracked catalyst is a Earnings expected August 18, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CING biotech catalysts?→
Add CING to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cingulate Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.